News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Expression Therapeutics Selects Advanced BioScience Laboratories, Inc. To Support Cell Line Development For Hemophilia A Factor VIII Infusion Therapy



8/18/2014 8:04:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TUCKER, Ga. & ROCKVILLE, Md.--(BUSINESS WIRE)--Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract research and manufacturing organization to the biopharmaceutical industry, announced today an agreement whereby ABL will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy. Expression Therapeutics’ recombinant factor VIII platform generates 100-fold greater expression than current products. ABL will adapt the current cell line to grow in chemically defined, animal origin-free media, and conduct optimization studies of cell growth conditions to support large scale production in a bioreactor-based process.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES